PPARA and metabolic dysfunction-associated steatohepatitis: Combined therapy with PPARα modulators pemafibrate and sodium‐glucose co‐transport 2 inhibitor tofogliflozin inhibits IRE1α‐XBP1‐PHLD3A pathway, reduces endoplasmic reticulum stress‐induced liver damage and has potential to treat NASH‐related HCC.102